Literature DB >> 15899779

Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance.

Satoru Munakata1, Omi Watanabe, Kazutomo Ohashi, Hideo Morino.   

Abstract

Apoptosis-related factors are known to influence survival with many malignant tumors. We performed immunohistochemical analysis of Fas ligand (FasL) and bcl-2 in invasive cervical cancer to determine the association with prognosis. In 125 patients with cervical cancer, 93 cases (74.4%) were positive for FasL, and 94 cases (75.2%) were positive for bcl-2. When 101 cases, clinical stages I through IV, were analyzed by univariate analysis, negative bcl-2 (P = .035) and combined positive FasL and negative bcl-2 (PFNB; P = .0025) were associated with significantly decreased disease-free survival. Positive FasL (P = .042), negative bcl-2 (P = .0004), and PFNB (P < .0001) were associated with a significantly worse prognosis in overall survival. In clinical stages II through IV, positive FasL (P = .04), negative bcl-2 (P = .002), and PFNB (P < .0001) had significant associations with shorter disease-free survival and positive FasL (P = .049), negative bcl-2 (P < .0001), and PFNB (P < .0001) with worse overall survival.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15899779     DOI: 10.1309/0773-N4Q3-GFP3-4J5V

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  The clinical significance of serum soluble Fas and p53 protein in breast cancer patients: comparison with serum CA 15-3.

Authors:  Taha I Hewala; Nadia A Abd El-Monaim; Medhat Anwar; Samia A Ebied
Journal:  Pathol Oncol Res       Date:  2012-03-17       Impact factor: 3.201

2.  Factors affecting platinum sensitivity in cervical cancer.

Authors:  Rina Kato; Kiyoshi Hasegawa; Yutaka Torii; Yasuhiro Udagawa; Ichio Fukasawa
Journal:  Oncol Lett       Date:  2015-09-25       Impact factor: 2.967

3.  Circulating levels of soluble Fas ligand reflect disease progression in multiple myeloma.

Authors:  Michael G Alexandrakis; Constantina A Pappa; Anna Kolovou; Stavroula Kyriakaki; Rodanthi Vyzoukaki; Maria Devetzoglou; George Tsirakis
Journal:  Med Oncol       Date:  2014-04-13       Impact factor: 3.064

4.  Serum sFas and tumor tissue FasL negatively correlated with survival in Egyptian patients suffering from breast ductal carcinoma.

Authors:  Ashgan I El-Sarha; Gehan M Magour; Sameh M Zaki; Mohamed Y El-Sammak
Journal:  Pathol Oncol Res       Date:  2008-11-18       Impact factor: 3.201

Review 5.  The role of CD95 and CD95 ligand in cancer.

Authors:  M E Peter; A Hadji; A E Murmann; S Brockway; W Putzbach; A Pattanayak; P Ceppi
Journal:  Cell Death Differ       Date:  2015-02-06       Impact factor: 15.828

6.  Cervical Cancer Cells Express Markers Associated with Immunosurveillance.

Authors:  Adriana Gutiérrez-Hoya; Octavio Zerecero-Carreón; Arturo Valle-Mendiola; Martha Moreno-Lafont; Rubén López-Santiago; Benny Weiss-Steider; Isabel Soto-Cruz
Journal:  J Immunol Res       Date:  2019-05-06       Impact factor: 4.818

7.  p53 and bcl2 expression in malignant and premalignant lesions of uterine cervix and their correlation with human papilloma virus 16 and 18.

Authors:  Shailaja Shukla; Jasmita Dass; Mukta Pujani
Journal:  South Asian J Cancer       Date:  2014-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.